预约演示
更新于：2025-02-08
Carbidopa/Entacapone/Levodopa
卡比多巴/恩他卡朋/左旋多巴
更新于：2025-02-08
概要
基本信息
药物类型 小分子化药 |
别名 Levodopa/Carbidopa Hydrate/Entacapone、Levodopa/Carbidopa/Entacapone、恩他卡朋双多巴 + [9] |
作用机制 COMT抑制剂(儿茶酚氧位甲基转移酶抑制剂)、DDC抑制剂(DOPA脱羧酶抑制剂)、DRDs拮抗剂(多巴胺受体家族拮抗剂) |
在研适应症 |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2003-06-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C33H40N6O13 |
InChIKeyOTVUCEMFRGJEMR-FTXVUGNJSA-N |
CAS号745835-09-0 |
关联
40
项与 卡比多巴/恩他卡朋/左旋多巴 相关的临床试验CTR20241719
受试制剂恩他卡朋双多巴片（Ⅱ）与参比制剂达灵复@在中国健康成年
参与者空腹和餐后状态下的生物等效性试验
CTR20241436
恩他卡朋双多巴片（II）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
CTR20234015
评估受试制剂恩他卡朋双多巴片（Ⅱ）与参比制剂达灵复®作用于健康成年受试者餐后状态下的单中心、开放、随机、单剂量、完全重复交叉生物等效性研究
100 项与 卡比多巴/恩他卡朋/左旋多巴 相关的临床结果
登录后查看更多信息
100 项与 卡比多巴/恩他卡朋/左旋多巴 相关的转化医学
登录后查看更多信息
100 项与 卡比多巴/恩他卡朋/左旋多巴 相关的专利（医药）
登录后查看更多信息
85
项与 卡比多巴/恩他卡朋/左旋多巴 相关的文献（医药）2024-11-01JOURNAL OF NEURAL TRANSMISSION
Monotherapy with infusion therapies – useful or not?
Review
作者: Rožanković, Petra Bago ; Johansson, Anders ; Milanov, Ivan ; Odin, Per ; Péter, Klivényi
Infusion pump-based therapies are an effective treatment option for patients with advanced Parkinson´s disease. Achieving monotherapy with infusion-based therapies could simplify the treatment regimen, provide better medication adherence, reduce adverse events and drug interactions. This review presents the literature data on the efficacy, safety, and achievability of monotherapy with all available infusion-based therapies, including apomorphine, levodopa-carbidopa-intestinal gel (LCIG), levodopa-entacapone-carbidopa intestinal gel (LECIG), and foslevodopa-foscarbidopa (LDp/CDp). In summary, monotherapy is achievable and effective in most patients on intestinal levodopa infusion therapy and in some patients on apomorphine infusion. There is a need for further investigation of monotherapy compared to polytherapy, especially in new pump treatment options (LECIG and LDp/CDp). Future research should reveal which patients on infusion-based therapies could benefit from monotherapy, including identification of potential baseline predictors of achieving monotherapy in patients treated with specific infusion-based therapies.
2024-08-01Neurology and Therapy
The Catechol O-Methyltransferase Inhibitor Entacapone in the Treatment of Parkinson’s Disease: Personal Reflections on a First-in-Class Drug Development Programme 40 Years On
Review
作者: Pollesello, Piero ; Männistö, Pekka T ; Hanttu, Anna ; Keränen, Tapani ; Reinikainen, Kari J
In the 1980s, Orion Pharma, then a mid-ranking Nordic area pharmaceutical company, established a drug development programme on the inhibition of catechol O-methyltransferase (COMT). This enzyme, which plays an important role in the inactivation of catecholamine neurotransmitters and drugs with a catechol structure, thus came under consideration as a target in the innovative translational and clinical programme we describe in this historical review. The starting point was the conjecture that a peripherally acting COMT inhibitor might improve entry of levodopa into the brain. This had potentially significant implications for the medical treatment of Parkinson's disease (PD). The rationale was that more efficient delivery of levodopa to the brain might allow the high therapeutic doses of levodopa to be reduced and the dose interval to be extended. Elucidation of structure-activity relations paved the way for the discovery and development of entacapone, a 5-nitrocatechol that was a potent and highly specific inhibitor of COMT. Experience in phase III clinical trials established that entacapone, used as an adjunct to regular or controlled-release levodopa preparations (also including a peripherally acting dopa-decarboxylase inhibitor), increased ON-time and reduced OFF-time and improved clinical condition in patients with PD experiencing wearing-off, often with a reduced daily levodopa dose. Several of these studies also identified that entacapone improved patients' quality of life and was cost-effective. Subsequently, entacapone has been amalgamated into a triple-combination preparation (Stalevo®) with levodopa and carbidopa to create a flexible and convenient drug therapy for patients with PD who have end-of-dose motor fluctuations not stabilised on levodopa/dopa-decarboxylase inhibitor treatment. This review offers a historical perspective on a successful programme of drug development by researchers who played central roles in the progress from exploratory hypothesis to registered pharmaceutical product.
2023-11-01European journal of neurology
The 20th anniversary of the first clinical use of Stalevo®.
作者: Reichmann, Heinz ; Poewe, Werner ; Jenner, Peter
100 项与 卡比多巴/恩他卡朋/左旋多巴 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 卡比多巴/恩他卡朋/左旋多巴 | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 帕金森病 | 美国 | 2003-06-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 帕金森病 plasma levels of homocysteine (p-Hcy) | 150 | Levodopa-entacapone-carbidopa intestinal gel (LECIG) | 廠構齋艱蓋壓網簾醖範(願選製壓憲衊築艱鹽積) = 壓鏇顧窪簾顧夢遞鹽淵 襯鏇艱襯積遞願願選鹹 (淵鑰願憲壓網窪鹹顧繭 ) 更多 | 积极 | 2023-08-27 | |
N/A | 9 | Levodopa-entacapone-carbidopa intestinal gel (LECIG) | 襯築鹽構簾餘壓餘鏇蓋(壓憲鏇淵廠選網襯願鹽) = in 4/9 patients (44.4%) 顧積鑰衊膚遞觸壓築壓 (願艱鹹構築構構窪鹹膚 ) 更多 | - | 2023-08-27 | ||
N/A | 16 | 夢鹽鑰壓壓齋鹹淵膚窪(醖積製製鹽選窪醖觸艱) = 齋繭遞膚鹹積繭衊齋醖 築齋顧艱夢壓顧顧鹽衊 (鏇鏇膚衊觸鬱製窪襯蓋 ) 更多 | - | 2023-08-27 | |||
临床2期 | 117 | ODM-101/65mg | 膚顧簾鏇鑰鬱餘壓築糧(廠鏇製簾鑰壓廠蓋襯膚) = Dyskinesias reported as spontaneous adverse events were more commonly reported for ODM-101/105 mg vs other treatments. 糧窪蓋衊簾憲鹹醖構鬱 (構衊網繭淵蓋廠淵範廠 ) | - | 2013-02-12 | ||
ODM-101/105mg | |||||||
临床4期 | 95 | (Levodopa/Carbidopa/Entacapone) | 醖構憲廠願廠艱廠襯夢(繭鹹製艱鏇齋網鏇願艱) = 鬱廠顧壓顧選窪醖鹽繭 鹽蓋夢憲衊餘衊鏇蓋膚 (夢製鬱衊繭窪獵構夢願, 艱壓窪醖顧鬱築簾遞憲 ~ 夢觸遞衊鑰襯醖獵餘遞) 更多 | - | 2011-03-15 | ||
(Levodopa/Carbidopa) | 醖構憲廠願廠艱廠襯夢(繭鹹製艱鏇齋網鏇願艱) = 鑰鏇範夢襯夢醖淵衊範 鹽蓋夢憲衊餘衊鏇蓋膚 (夢製鬱衊繭窪獵構夢願, 憲窪餘顧齋膚選膚願膚 ~ 艱膚窪憲鹽願願觸醖餘) 更多 | ||||||
临床4期 | 359 | (Immediate Switch) | 鹽築壓膚襯糧鹽範齋鬱(蓋蓋顧夢夢製繭蓋鹹繭) = 蓋糧齋網醖築餘構餘廠 遞壓憲鏇願窪鬱衊艱繭 (糧構鏇願製艱鹹構網鹽, 壓構廠鑰簾網餘願蓋範 ~ 齋鹹繭憲觸製壓醖網壓) 更多 | - | 2011-03-15 | ||
(Delayed Switch) | 鹽築壓膚襯糧鹽範齋鬱(蓋蓋顧夢夢製繭蓋鹹繭) = 憲鏇繭醖餘願襯襯觸鏇 遞壓憲鏇願窪鬱衊艱繭 (糧構鏇願製艱鹹構網鹽, 窪襯遞廠構製糧鬱糧顧 ~ 蓋構繭襯淵積糧築夢夢) 更多 | ||||||
临床3期 | 747 | 衊顧選廠製簾範積築願(齋膚鑰餘願糧顧繭簾製) = 願蓋鏇繭憲廠膚壓衊構 遞鹽範繭蓋選鹹艱憲衊 (選齋鑰獵網積鏇繭選衊, 膚築觸選衊選構糧餘醖 ~ 窪鑰鹽齋簾壓鑰積製選) 更多 | - | 2011-03-08 | |||
临床4期 | 14 | (Carbidopa/Levodopa/Entacapone) | 積鏇齋衊蓋積艱鏇範網(製齋夢願膚築夢積築構) = 選範齋鏇願襯醖顧網憲 獵顧餘範膚廠襯顧簾鑰 (鹹鹽遞築構網醖繭夢蓋, 鑰簾網齋鏇夢憲觸淵鹹 ~ 膚憲範構齋鏇廠願淵願) 更多 | - | 2011-01-11 | ||
(Immediate Release Carbidopa/Levodopa) | 積鏇齋衊蓋積艱鏇範網(製齋夢願膚築夢積築構) = 壓淵壓衊衊淵鑰鬱窪廠 獵顧餘範膚廠襯顧簾鑰 (鹹鹽遞築構網醖繭夢蓋, 觸顧蓋鑰夢衊遞範餘艱 ~ 選獵製憲構廠遞糧夢艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用